The DOI matches its Crossref record.
Nationwide Survey of Drug-Resistant Tuberculosis in the United States
Abstract
OBJECTIVE: To determine antituberculosis drug resistance patterns, geographic distribution, demographic characteristics, and risk factors of reported tuberculosis (TB) patients in the United States. DESIGN: Survey of reported TB cases in the United States. For culture-positive cases reported to the Centers for Disease Control and Prevention, we asked health departments to provide drug susceptibility test results from initial Mycobacterium tuberculosis isolates. STUDY POPULATION: Culture-positive TB cases in the United States reported during the first quarter of 1991. MAIN OUTCOME MEASURES: Individual TB case reports submitted to the Centers for Disease Control and Prevention and drug susceptibility test results. RESULTS: Resistance to one or more antituberculosis drugs was found in 14.2% of cases. Resistance to isoniazid and/or rifampin was found in 9.5% of cases whose isolates were tested against one or both drugs; such cases were found in 107 counties in 33 states. Resistance to both isoniazid and rifampin (multidrug-resistant [MDR] TB) was found in 3.5% of cases whose isolates were tested against both drugs; such cases were found in 35 counties in 13 states. New York City accounted for 61.4% of the nation's MDR TB cases. The 3-month population-based incidence rate of MDR TB in New York City was 52.4 times (95% confidence interval [CI], 35.5 to 78.3) that of the rest of the nation (9.559 vs 0.182 cases per million population). Compared with the rate in non-Hispanic whites in the rest of the nation (0.032 cases per million), the relative risk of MDR TB in New York City non-Hispanic whites was 39.0 (95% CI, 8.1 to 164.5), 299.3 (95% CI, 112.5 to 927.1) in Hispanics, 420.9 (95% CI, 121.0 to 1515.8) in Asian/Pacific Islanders, and 701.0 (95% CI, 296.4 to 2018.1) in non-Hispanic blacks. CONCLUSIONS: With nearly 10% of TB patients resistant to isoniazid and/or rifampin, greater use of four-drug regimens and directly observed therapy is indicated. Aggressive intervention to prevent the further spread of MDR TB is needed to find every TB patient and to provide optimal patient management to ensure completion of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Scorpio, A., & Zhang, Y. (1996) · Nature Medicine · doi:10.1038/nm0696-662 · Cited by 726
Antimicrobial agent resistance in mycobacteria: molecular genetic insights
Musser, J. M. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.496 · Cited by 621
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Bifani, P. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530300036037 · Cited by 381
Cohn, D. L., Bustreo, F., & Raviglione, M. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.supplement_1.s121 · Cited by 340
Metadata
- Authors
- Bloch, A. B.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1994-03-02
- Volume
- 271
- Issue
- 9
- Pages
- 665
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2009290349
- Cited by
- 304
- References
- 0
- FWCI
- 44.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nationwide Survey of Drug-Resistant Tuberculosis in the United States. https://app.cochat.ai/papers/10.1001/jama.1994.03510330043032
- The paper
- Bloch, A. B. (1994). Nationwide Survey of Drug-Resistant Tuberculosis in the United States. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1994.03510330043032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.